Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03905447
Other study ID # PC_ASP_002
Secondary ID 2018-000240-26
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 17, 2019
Est. completion date June 1, 2020

Study information

Verified date June 2020
Source Pulmocide Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study tests the effects of pre-emptive treatment with an experimental drug PC945 in lung transplant recipients whose lungs are infected by the fungus Aspergillus fumigatus. PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will be monitored for up-to 12 weeks for the presence of Aspergillus in their lungs. Suitable participants will receive PC945 for an initial 28 days (Pre-emptive treatment phase) and, if needed, a further 8-weeks (Extended treatment phase).The amount of fungus in the patients' lungs will be measured over the course of the study. Participants with lung infections but not eligible for PC945 will be followed-up for 16-weeks on standard of care treatment. The study will take place at multiple sites in UK and 10 participants will receive PC945. The maximum study duration will be about 28 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date June 1, 2020
Est. primary completion date June 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria (Surveillance Phase) - Between the ages of 18 and 85 years. - Received a single or bilateral lung transplant. - Provided written informed consent prior to transplant Exclusion Criteria (Surveillance Phase) - Is precluded from participating in this study as a result of treatment with another investigational drug or participation in another clinical trial. - If female, the subject is pregnant, lactating or breast feeding. - Any other clinically significant disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial (e.g., recent myocardial infarction). - Is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study. - Is receiving antiretroviral protease inhibitor therapy. - Has human immunodeficiency virus or chronic, active hepatitis infection, or had a positive hepatitis B surface antigen or hepatitis C virus RNA test prior to transplant. - Any known history or current evidence of alcohol or drug abuse that, in the Investigator's opinion, would exclude the subject from participation in the study Inclusion Criteria (Pre-emptive Treatment Phase) - A positive test for A. fumigatus in BAL during the Surveillance Phase of the study - Provided written informed consent for participating in the Pre-Emptive Treatment Phase. Exclusion Criteria (Pre-emptive Treatment Phase) - Clinical, endobronchial and/or radiological features of fungal disease.* - Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in the Pre-Emptive Treatment Phase of the study (e.g., recent myocardial infarction). Inclusion Criteria (Follow-up Phase - SOC Antifungal Treatment) - Subject is not eligible to receive pre-emptive PC945 treatment due to either clinical, endobronchial and/or radiological features of fungal disease OR a fungal infection other than A. fumigatus in BAL, that requires SoC antifungal treatment to be started during the Surveillance Phase of the study. - Provided written informed consent for participating in the Follow-Up Phase for SoC antifungal treatment. Exclusion Criteria (Follow-up Phase - SOC Antifungal Treatment) - Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in the Follow-Up Phase for SoC antifungal treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PC945
Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
Standard of Care
Standard of Care antifungal medication

Locations

Country Name City State
United Kingdom Harefield Hospital Harefield Uxbridge
United Kingdom Wythenshawe Hospital Manchester
United Kingdom Papworth Hospital Papworth Everard Cambridge

Sponsors (1)

Lead Sponsor Collaborator
Pulmocide Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events (AEs) 48 hours Post Transplant to Week 16 post treatment
Primary Proportion of participants receiving PC945 who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose Baseline to Week 16
Primary Proportion of participants receiving PC945 who meet the markedly abnormal criteria for vital signs assessment at lease once post dose Baseline to Week 16
Primary Proportion of participants receiving PC945 who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose Baseline to Week 16
Primary Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values from participants receiving PC945 Baseline to Week 16
Primary Forced vital capacity (FVC) values from participants receiving PC945 Baseline to Week 16
Primary Area under the curve from time 0 to 2 h post-dose (AUC0-2) Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable Baseline to Week 16
Primary Maximum plasma concentration Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable Baseline to Week 16
Primary Concentration at the end of the dosage interval (Ctrough) Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable Baseline to Week 16
Secondary Lung Concentration of PC945 Baseline to Week 16
Secondary A. fumigatus fungal culture status (presence or absence) in subjects with a baseline A. fumigatus-positive bronchoalveolar lavage (BAL) Baseline to Week 16
Secondary Change in BAL A. fumigatus measured by quantitative polymerase chain reaction (qPCR) Baseline to Week 16
Secondary Change in the number of sputum A. fumigatus colony forming units (CFU) in cultured BAL. Baseline to Week 16
Secondary Galactomannan levels in BAL Baseline to Week 16
Secondary Aspergillus status (Presence or absence) of BAL using an Aspergillus immunochromatographic lateral flow device (AspLFD). Baseline to Week 16
Secondary Status of fungal hyphae or pseudohyphae (presence or absence) on cytological examination Baseline to Week 16
Secondary Subject experience of inhaled PC945 Assessed by a standardised study-specific questionnaire assessing participants' subjective experience across a number of domains including taste, smell and overall acceptability following inhalation of PC945. Baseline to Week 16
Secondary Subject experience of inhaled amphotericin B Assessed by a standardised study-specific questionnaire assessing participants' subjective experience across a number of domains including taste, smell and overall acceptability, following inhalation of amphotericin B. Baseline to Week 16
See also
  Status Clinical Trial Phase
Suspended NCT01887457 - Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy Phase 2
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Enrolling by invitation NCT01617759 - Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
Recruiting NCT04744454 - Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
Completed NCT02715570 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945 Phase 1
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Completed NCT04935463 - Mucormycosis in COVID-19
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00473252 - Surveillance of Fungal Infections During Construction Activity N/A
Completed NCT00037206 - A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Phase 2/Phase 3
Completed NCT04818853 - COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Recruiting NCT06135597 - Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
Terminated NCT02646800 - Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Phase 4
Completed NCT00854607 - An Observational Study of Fungal Biomarkers (MK-0000-089) N/A
Completed NCT00388167 - Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Phase 4
Completed NCT05065658 - Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Completed NCT00005912 - Voriconazole to Prevent Systemic Fungal Infections in Children Phase 1
Completed NCT04431804 - THYME AND CARVACROLL Nanoparticle Effect on Fungi